The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Chemotherapy often generates intratumoral senescent cancer cells that strongly modify the tumor microenvironment, favoring immunosuppression and tumor growth. We discovered, through an unbiased proteomics screen, that the immune checkpoint inhibitor programmed cell death 1 ligand 2 (PD-L2) is highly upregulated upon induction of senescence in different types of cancer cells. PD-L2 is not required for cells to undergo senescence, but it is critical for senescent cells to evade the immune system and persist intratumorally. Indeed, after chemotherapy, PD-L2-deficient senescent cancer cells are rapidly eliminated and tumors do not produce the senescence-associated chemokines CXCL1 and CXCL2. Accordingly, PD-L2-deficient pancreatic tumors fail to recruit myeloid-derived suppressor cells and undergo regression driven by CD8 T cells after chemotherapy. Finally, antibody-mediated blockade of PD-L2 strongly synergizes with chemotherapy causing remission of mammary tumors in mice. The combination of chemotherapy with anti-PD-L2 provides a therapeutic strategy that exploits vulnerabilities arising from therapy-induced senescence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“changes in MoCA scores were negatively correlated with changes in TNF-α and PDL-2 (a recently proposed serum marker of senescence47), such that larger reductions in these biomarkers were strongly and significantly correlated with larger improvements in MoCA scores.”
From A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer's disease (2025) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“51) was used for differential expression analysis with fold change shrinkage as implemented in the lfcShrink function.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 1×
“A total of 10 6 SK-MEL-103 cells, either PD-L2 WT or PD-L2 KO, were collected, resuspended in a volume of 100 μl PBS/Matrigel and injected in both flanks of 8–16-week-old female athymic nude mice.”
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · cited 1×
“Interestingly, chemotherapy controlled the growth of PD-L2 KO tumors significantly better than their WT counterparts spectrum of tumors 3–5 , including melanoma and non-small cell lung cancer 6 .”
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206 · cited 6×
“The SASP is complex and heterogeneous, including pro-inflammatory cytokines, chemokines, matrix remodeling enzymes and growth factors, which result in cell-extrinsic effects known to facilitate tumor growth 22–25 .”
InfluentialThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Interestingly, chemotherapy controlled the growth of PD-L2 KO tumors significantly better than their WT counterparts spectrum of tumors 3–5 , including melanoma and non-small cell lung cancer 6 .”
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · cited 1×
“14,15).”
Cited by
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A.-A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 229
Montégut, L., López-Otín, C., & Kroemer, G. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02020-z · Cited by 190
“Moreover, senescence can result in local immunosuppression due to upregulation of the two PD-1 ligands PD-L1 and/or PD-L2 on malignant cells [70, 71], as well as in the secretion of pro-inflammatory and immunosuppressive factors exemplified by interleukins 6 and 8 [72].”
BackgroundSenescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
“53) — can impair its clearance.”
Colucci, M., Sarill, M., Maddalena, M., Valdata, A., Troiani, M., Massarotti, M., Bolis, M., Bressan, S., Kohl, A., Robesti, D., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.015 · Cited by 164
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 119
“For example, senescent cancer cells can upregulate the immune checkpoint ligand PDL2, which protects both senescent and viable cancer cells from T cell killing 68 .”
Metadata
- Authors
- Chaib, S., López-Domínguez, J. A., Lalinde-Gutiérrez, M., Prats, N., Marin, I., Boix, O., García-Garijo, A., Meyer, K., Muñoz, M. I., Aguilera, M., Mateo, L., Stephan-Otto Attolini, C., Llanos, S., Pérez-Ramos, S., Escorihuela, M., Al-Shahrour, F., Cash, T. P., Tchkonia, T., Kirkland, J. L., Abad, M., Gros, A., Arribas, J., & Serrano, M.
- Affiliations
- Mayo Clinic (US)
- Vall d'Hebron Institute of Oncology (ES)
- Institute for Research in Biomedicine (ES)
- Spanish National Cancer Research Centre (ES)
- Altos Labs (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Serrano, Manuel
- ORCID
- Chaib, Selim
- López-Domínguez, José Alberto
- Lalinde-Gutiérrez, Marta
- Prats, Neus
- Boix, Olga
- García-Garijo, Andrea
- Meyer, Kathleen
- Aguilera, Mònica
- Mateo, Lidia
- Stephan-Otto Attolini, Camille
- Llanos, Susana
- Pérez-Ramos, Sandra
- Escorihuela, Marta
- Al-Shahrour, Fatima
- Tchkonia, Tamara
- Kirkland, James L.
- Abad, María
- Gros, Alena
- Arribas, Joaquín
- Serrano, Manuel
- Venue
- Nature Cancer
- Published
- 2024-01-24
- Volume
- 5
- Issue
- 3
- Pages
- 448-462
- ISSN
- 2662-1347 (ISSN-L)
- PMC
- PMC10965441
- OpenAlex
- W4391175022
- Cited by
- 114
- References
- 56
- Citations by year
- 2026: 40 · 2025: 39 · 2024: 35
- FWCI
- 32.44
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-05-29)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Gredos (University of Salamanca) (publishedVersion, cc-by-nc-nd)
- Hispana (publishedVersion, cc-by-nc-nd)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (acceptedVersion, cc-by)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- Funders
- Breast Cancer Research Foundation (BCRF-21-008, BCRF-21)
- Fundación BBVA (53/2021, MS15/00058)
- Noaber Foundation
- European Commission (ERC-2014-AdG)
- Generalitat de Catalunya (2017-SGR)
- Ministerio de Ciencia e Innovación (SAF2017-82613-R, 2017 SGR 282)
- Banco Bilbao Vizcaya Argentaria
- Universitat de Barcelona
- National Institutes of Health
- Instituto de Salud Carlos III (CB16/12/00449, PI19/01181, AC15/00062, MS15/00058)
- European Regional Development Fund (SAF2017, 2017 SGR 282, SAF2017-82613-R, RTI2018, ERC-2014- AdG/669622)
- National Institute on Aging (UH3AG056933, R01AG072301, UH2AG056933, R01AG013925, R56AG061414, R33AG061456, R37AG013925, P01AG062413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L2, chemotherapy-induced senescence, tumor microenvironment, myeloid-derived suppressor cells, CXCL1, CXCL2, CD8+ T cells, combination therapy, pancreatic tumors, mammary tumors, immune checkpoint inhibitors
- MeSH terms
- Animals, Immune Tolerance, Immunosuppression Therapy, Pancreatic Neoplasms, Cellular Senescence, CD8-Positive T-Lymphocytes, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. https://app.cochat.ai/papers/10.1038/s43018-023-00712-x
- The paper
- Chaib, S., López-Domínguez, J. A., Lalinde-Gutiérrez, M., Prats, N., Marin, I., Boix, O., García-Garijo, A., Meyer, K., Muñoz, M. I., Aguilera, M., Mateo, L., Stephan-Otto Attolini, C., Llanos, S., Pérez-Ramos, S., Escorihuela, M., Al-Shahrour, F., Cash, T. P., Tchkonia, T., Kirkland, J. L., . . . Serrano, M. (2024). The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nature Cancer. https://doi.org/10.1038/s43018-023-00712-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.